Show simple item record

dc.contributor.advisorJosé, Esguerra
dc.contributor.authorGonzalez Álvarez, Iván Darío
dc.contributor.otherJimenez, Adriana
dc.contributor.otherEsguerra, José
dc.contributor.otherRojas, Fernando
dc.contributor.otherCamargo, Jennifer
dc.contributor.otherMorals, Laura
dc.coverage.spatialInstituto Nacional de Cancerología - Colombiaspa
dc.coverage.temporal2018 - 2020spa
dc.date.accessioned2021-02-22T16:16:11Z
dc.date.available2021-02-22T16:16:11Z
dc.date.issued2021-01-25
dc.identifier.urihttp://hdl.handle.net/10654/37414
dc.description.abstractLos tumores primarios oculares más frecuentes en la población adulta y pediátrica son el melanoma y el retinoblastoma, respectivamente. El tratamiento de estas patologías es un reto para el médico tratante, ya que debe balancear la necesidad de control de la enfermedad, frente a la conservación del órgano y su función, especialmente en el escenario de enfermedad localizada. Lo anterior, por lo general se logra mediante la combinación de terapias de control local y se prefiere sobre la enucleación. Desde su implementación, la braquiterapia ocular se ha consolidado como una alternativa terapéutica que alcanza un adecuado control local, a la vez que permite la conservación del globo ocular y preserva la visión. Con este estudio se busca describir la efectividad y seguridad de la braquiterapia ocular, en una serie consecutiva de pacientes, tratados en nuestra institución.spa
dc.description.tableofcontentsResumen del manuscrito Introducción Materiales y métodos Resultados Discusión Conflicto de intereses Fuentes de financiación Referenciasspa
dc.format.mimetypeapplicaction/pdfspa
dc.language.isospaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleEfectividad y seguridad de la braquiterapia ocular, experiencia del Instituto Nacional de Cancerología, años 2010 a 2018spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2*
dc.type.localTesis/Trabajo de grado - Monografía - Especializaciónspa
dc.description.abstractenglishThe most common primary ocular tumors in the adult and pediatric population are melanoma and retinoblastoma, respectively. The treatment of these pathologies is a challenge for the treating physician, since he must balance the need to control the disease, against the preservation of the organ and its function, especially in the setting of localized disease. This is generally accomplished by combining local control therapies and is preferred over enucleation. Since its implementation, ocular brachytherapy has established itself as a therapeutic alternative that achieves adequate local control, while allowing the preservation of the eyeball and preserving vision. This study seeks to describe the effectiveness and safety of ocular brachytherapy in a consecutive series of patients treated at our institution.spa
dc.title.translatedEffectiveness and safety of ocular brachytherapy, experience of Instituto Nacional de Cancerología, years 2010 to 2018spa
dc.subject.keywordsOcular brachytherapyspa
dc.subject.keywordsPlaque radiotherapyspa
dc.subject.keywordsRetinoblastomaspa
dc.subject.keywordsOcular melanomaspa
dc.subject.keywordsSurvivalspa
dc.subject.keywordsLocal controlspa
dc.publisher.programOncología Radioterápicaspa
dc.creator.degreenameEspecialista en Oncología Radioterápicaspa
dc.subject.decsOncologíaspa
dc.subject.decsRadioterapiaspa
dc.subject.decsRadiocirugiaspa
dc.subject.decsBraquiterapiaspa
dc.contributor.corporatenameInstituto Nacional de Cancerología - Colombiaspa
dc.description.degreelevelEspecializaciónspa
dc.publisher.facultyFacultad de Medicinaspa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.rights.creativecommonsAttribution-NonCommercial-NoDerivatives 4.0 Internationalspa
dc.relation.references1. Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer Eye. 2017;31,241–57spa
dc.relation.references2. Singh AD, Turell ME, Topham AK, Uveal Melanoma: Trends in Incidence, Ophthalmology. 2011;118(9):1881-5.spa
dc.relation.references3. Raksha R, Santosh GH. Retinoblastoma. Indian J Pediatr 2017; 84(12):937–944spa
dc.relation.references4. Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, Brisse H, Doz F, Desjardins L. Retinoblastoma. Orphanet Journal of Rare Diseases. 2006; 1:31, 1- 11spa
dc.relation.references5. Moore R, Choroidal sarcoma treated by the intraocular insertion of radon seeds. Br J Ophthalmol.1930;14:145-56spa
dc.relation.references6. American Brachytherapy Society - Ophthalmic Oncology Task Force. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1-14.spa
dc.relation.references7. Francis JH, Barker CA, Wolden SL, et al.: Salvage/adjuvant brachytherapy after ophthalmic artery chemosurgery for intraocular retinoblastoma. Int J Radiat Oncol Biol Phys. 2013; 87(3): 517–23spa
dc.relation.references8. Brewington BY, Shao YF, Davidorf FH, Cebulla CM, Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions, Clinical Ophthalmology 2018:12, 925–34spa
dc.relation.references9. Jampol LM, Moy CS, Murray TG, et al. The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma: V. Twelve-Year Mortality Rates and Prognostic Factors: COMS Report No. 28. Arch Ophthalmol. 2006;124(12):1684–93spa
dc.relation.references10. Melia BM, Abramson DH, Albert DM, et al. Collaborative Ocular Melanoma Study Group. Collaborative ocular melanoma study (COMS) 25 randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001 Feb;108(2):348-66.spa
dc.relation.references11. Messer JA, Zuhour RJ, Haque W. Eye plaque brachytherapy versus enucleation for ocular melanoma: an analysis from the National Cancer Database. J Contemp Brachytherapy 2020; 12, 4: 303–10spa
dc.relation.references12. Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: A 2020 review. Indian J Ophthalmol 2020;68:2356-65spa
dc.relation.references13. Shields CL, Shields JA, Minelli S, De Potter P, Hernandez C, Cater J, Brady L, Regression of Retinoblastoma After Plaque Radiotherapy. American Journal of Ophthalmology, 1993.115(2),181–7.spa
dc.relation.references14. Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, Freire J. Plaque radiotherapy for large posterior uveal melanomas (≥8-mm thick) in 354 consecutive patients Ophthalmology, 2002.109(10),1838-49.spa
dc.relation.references15. Wen JC, Oliver SC, McCannel TA. Ocular complications following I-125 brachytherapy for choroidal melanoma. Eye, 2009. 23,1254–68spa
dc.relation.references16. Read W, Crump RT, Weis E. Journal of Medical Imaging and Radiation Sciences. 2016, 47.349-55spa
dc.subject.proposalBraquiterapia ocularspa
dc.subject.proposalRadioterapia de placaspa
dc.subject.proposalRetinoblastomaspa
dc.subject.proposalMelanoma ocularspa
dc.subject.proposalSupervivenciaspa
dc.subject.proposalControl localspa
dc.publisher.grantorUniversidad Militar Nueva Granadaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1f*
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.identifier.instnameinstname:Universidad Militar Nueva Granadaspa
dc.identifier.reponamereponame:Repositorio Institucional Universidad Militar Nueva Granadaspa
dc.identifier.repourlrepourl:https://repository.unimilitar.edu.cospa
dc.rights.localAcceso abiertospa
dc.coverage.sedeMedicinaspa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/